165 related articles for article (PubMed ID: 22950939)
1. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies.
Tam CS
Leuk Lymphoma; 2013 Feb; 54(2):215-6. PubMed ID: 22950939
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.
Xu XJ; Zhao HZ; Tang YM
Leuk Lymphoma; 2013 Feb; 54(2):255-60. PubMed ID: 22897728
[TBL] [Abstract][Full Text] [Related]
3. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
Oh I; Oh Y; Ohmine K
Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
[TBL] [Abstract][Full Text] [Related]
5. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
6. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
[TBL] [Abstract][Full Text] [Related]
7. Are all chimeric antigen receptors created equal?
Park JH; Brentjens RJ
J Clin Oncol; 2015 Feb; 33(6):651-3. PubMed ID: 25605860
[No Abstract] [Full Text] [Related]
8. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.
Numbenjapon T; Serrano LM; Singh H; Kowolik CM; Olivares S; Gonzalez N; Chang WC; Forman SJ; Jensen MC; Cooper LJ
Leukemia; 2006 Oct; 20(10):1889-92. PubMed ID: 17041638
[No Abstract] [Full Text] [Related]
11. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
12. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
13. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy hits the market.
Boyer MW
Immunotherapy; 2018 Aug; 10(11):911-912. PubMed ID: 30149765
[No Abstract] [Full Text] [Related]
15. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
Riddell SR; Sommermeyer D; Berger C; Liu LS; Balakrishnan A; Salter A; Hudecek M; Maloney DG; Turtle CJ
Cancer J; 2014; 20(2):141-4. PubMed ID: 24667960
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.
Hao L; Li T; Chang LJ; Chen X
Curr Med Chem; 2019; 26(17):3068-3079. PubMed ID: 28762313
[TBL] [Abstract][Full Text] [Related]
17. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
[TBL] [Abstract][Full Text] [Related]
18. Universal CAR T Cells Treat Leukemia.
Cancer Discov; 2017 Apr; 7(4):342. PubMed ID: 28193774
[TBL] [Abstract][Full Text] [Related]
19. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
20. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]